CA2407140A1 - Directly compressed solid dosage particles - Google Patents
Directly compressed solid dosage particles Download PDFInfo
- Publication number
- CA2407140A1 CA2407140A1 CA002407140A CA2407140A CA2407140A1 CA 2407140 A1 CA2407140 A1 CA 2407140A1 CA 002407140 A CA002407140 A CA 002407140A CA 2407140 A CA2407140 A CA 2407140A CA 2407140 A1 CA2407140 A1 CA 2407140A1
- Authority
- CA
- Canada
- Prior art keywords
- weight
- copolymer
- granulated
- cross
- modifying polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
Solid dosage articles such as pharmaceutical tablets for the controlled release of a desired compound such as an active ingredient are directly compressed from a flowable, compressible mixture of the active ingredient, a slightly cross-linked rheology modifying polymer or copolymer, and one or mo re excipients. The rheology modifying polymer or copolymer is a granulated powd er of suitable particle size and is generally made from one or more unsaturated (di)carboxylic acids, half ester thereof, and other optional monomers.</SDOA B>
Description
DIRECTLY COMPRESSED SOLID DOSAGE ARTICLES
FIELD OF INVENTION
The present invention relates to slightly cross-linked polymers and copolymers generally derived from one or more unsaturated carboxylic acids, which are mixed with one or more active ingredients, and one or more excipients, wherein the mixture has desired properties such as good flow rates and appropriate compressibility so that without further processing it can flow through a die and be directly compressed into a tablet or other solid dosage article.
BACKGROUND OF THE INVENTION
1 ~ Heretofore, rheology agents were generally unsuitable for utiliza-tion in the formation of directly compressed tablets generally due to their fine particle size, static generating nature, and poor flow characteristics which they imparted to powder mixtures such as pharmaceutical mixtures.
In order to form such powder mixtures, a rheologic agent in the form of a ?0 non-granulated powder was mixed with an active ingredient and an excipi-ent and granulated. Subsequently, the granulated mixture was com-pressed into a tablet. The rheologic agents utilized included compounds such as Carbopol~ 934 PNF, 971 PNF, 974 PNF, 940, 941, and 934 made by B. F. Goodrich Company. Other similar rheologic agents include Syn-thalen K, L, and M made by 3V/Sigma, Hivis Wako made by Wako Pure Chemicals Co., and Aqupec made by Sumitomo Seika.
SUMMARY OF INVENTION
30 Solid dosage forms such as tablets for pharmaceutical uses are directly compressed from a mixture of granular rheology modifying poly-mers or copolymers, active ingredients, and excipients. The rheology modifier is a homopolymer or copolymer derived from one or more unsatu-rated carboxylic acids and is slightly cross-linked. The rheology modifying polymer or copolymer is processed into a desirable granular size as by be-ing compacted into large agglomerates or aggregates and subsequently fractured into smaller granules and generally screened to obtain suitable particle sizes which have low amounts of dust. The polymer or copolymer becomes highly swollen in an aqueous medium and is suitable for use in a human being or animal. The polymer or copolymer can be combined with numerous different types of active ingredients for one or more specific end uses. Moreover, numerous different types of excipients can be utilized.
The combination of the one or more excipients, active ingredients, and the theology modifying polymer or copolymer when mixed generally form suit-able mixtures for directly compressible tablets because of their good flow characteristics and compressibility.
DESCRIPTION OF THE DRAWINGS
1 ~ The figure is a schematic of a compaction/granulation appa-ratus.
DETAILED DESCRIPTION OF THE INVENTION
The polymeric theology modifier provides controlled release of ?0 biologically active compounds as contained in a tablet so that when placed in water, the modifier of the invention swells to form a viscous gel which retards diffusion of the active material. The theology modifying polymers or copolymers are derived from one or more unsaturated carboxylic acid monomers generally having one or two carboxylic acid groups, desirably having one carbon to carbon double bond and containing generally a total of from 3 to about 10 carbon atoms and preferably from 3 to about 5 car-bon atoms such as a-~3-unsaturated monocarboxylic acids, for example, acrylic acid, methacrylic acid, and crotonic acid, and the like, or dicarboxylic acids such as itaconic acid, fumaric acid, malefic acid, aconitic acid, and the 30 like. Moreover, half ester monomers of such diacids with alkanols contain-ing from 1 to about 4 carbon atoms can also be utilized. Preferred acids in-clude acrylic acid or malefic acid.
Optionally, one or more oxygen containing unsaturated co-monomers having a total of from 3 to about 40 carbon atoms, such as es-ters of the above unsaturated (di)carboxylic acids, that is mono or di, espe-cially alkyl esters containing a total of from 1 to about 30 carbon atoms in the alkyl group can also be utilized as comonomers to form the copolymer.
Examples of such esters include ethyl acrylate, butyl acrylate, 2-ethylhexyl acrylate, dodecyl acrylate, hexadecyl acrylate, and octadecyl acrylate, and the like, with the C,° to C3° acrylates being preferred.
Another optional class of comonomers are the various anhy-drides of the above noted carboxylic acids such as malefic anhydride, and the like. Moreover, another optional class of suitable comonomers are the various alkyl vinyl ethers wherein the alkyl group contains from 1 to about 1 > 20 carbon atoms with examples including ethyl vinyl ether, methyl vinyl ether, and the like.
The amount of the one or more oxygen containing acid co-monomers when utilized is generally a minor amount, such as from about 0.01 % to about 40% by weight, desirably from about 0.5% to about 35% by ?0 weight, and preferably from about 1 % to about 25% by weight based upon the total weight of all the Theology modifying polymer or copolymer forming monomers and comonomers. Thus, the amount of the one or more un-saturated carboxylic acid monomers, half esters thereof, or combinations thereof, is generally from about 60% to 99.99% by weight, desirably from about 65% to about 99.5% by weight, and preferably from about 75% to about 99% by weight based upon the total weight of all Theology modifying polymer or copolymer forming monomers or comonomers.
The various Theology modifying polymers or copolymers of the present invention are generally anhydrous. That is, they generally contain 30 5 parts by weight or less, desirably 3 parts or 2 parts by weight or less, and preferably 1 part or less by weight, and even nil, that is no parts by weight, of water per 100 parts by weight of the one or more rheology modifying polymers or copolymers.
The one or more rheology modifying polymers or copolymers also generally contain low amounts by weight of multivalent metal cations such as iron, for example 1 part by weight or less, desirably 0.1 part by weight or less, and preferably 0.01 part by weight or less per 100 parts by weight of all rheology modifying polymers or copolymers. The rheology modifying polymers or copolymers can contain up to five parts by weight of monovalent metal cations such as sodium, potassium, and the like.
It is an important aspect of the present invention that the rheol-ogy modifying polymer or copolymer be slightly cross-linked with one or more polyunsaturated monomers or comonomers. Suitable cross-linking agents generally include the various allyl ethers of sucrose or pentaerythri-tol, or derivatives thereof, or various polyalcohols. Specific examples in-I ~ clude; diallylphthalate, divinyl benzene, allyl (meth)acrylate, ethylene glycol di(meth)acrylate, divinylglycol methylene bisacrylamide, trimethylolpropane tri(meth)acrylate, diallyl itaconate, diallyl fumarate, or diallyl maleate. De-rivatives of castor oils or polyols such as esterfied with an ethylenically un-saturated carboxylic acid and the like can also be used. Preferred cross-~0 linking agents include allyl ether of sucrose, allyl ether of pentaerythritol, di-allylphthalate, and combinations thereof.
The amount of the cross-linking agent is from about 0.01 to about 2 parts by weight, desirably from about 0.02 to about 1.5 parts by weight, and preferably from about 0.03 to about 1 part by weight per 100 total parts by weight of the one or more monomers or comonomers.
Slightly cross-linked rheology modifying polymers or copolymers are util-ized inasmuch as they can conform under light pressure as in a compacting apparatus and in a mill to form granular mixtures which readily flow. Highly cross-linked rheology modifying polymers or copolymers tend to not con-30 form under light pressure and consequently fracture in a mill thus forming fine sized particles which do not readily flow and are therefore unsuitable for forming a directly compressed solid dosage form. Such moderate to highly cross-linked polymers or copolymers also tend to generate fisheyes therein. That is, when placed in water, they exhibit incompletely swollen particles easily visible in the transparent gel. , Examples of suitable slightly cross-linked commercially available theology modifying polymers or copolymers include Carbopol~, 941, 971 PNF and 981 manufactured by B. F.Goodrich, as well as Synthalen L made by 3V/Sigma, Aqupec HV-501 and HV 501 E made by Sumitomo Seika.
The polymers or copolymers of the present invention are pro-duced by conventional methods known to the art and to the literature such as by dispersion or precipitation polymerization utilizing suitable organic solvents such as various hydrocarbons, esters, halogenated hydrocarbon compounds and the like, with specific examples including aromatic solvents such as benzene, or toluene; various cycloaliphatic solvents such as cyclo-1 ~ hexane; various esters such as ethyl acetate and methyl formate, ethyl formate; various chlorinated hydrocarbons such as dichloromethane; and combinations thereof. Preferred solvents generally include benzene, meth-ylene chloride, blends of ethyl acetate and cyclohexane, or ethyl acetate, and the like.
'_'U The one or more monomers or comonomers are polymerized in a manner known to the art and to the literature such as described in U.S.
Patent Nos. 2,798,053; 3,915,921; 4,267,103; 5,288,814; and 5,349,030 which are hereby fully incorporated by reference. Desirably, the theology modifying polymers or copolymers have an acidic pH in water as from about 2.0 to about 4.0, desirably from about 2.5 to about 3.5.
It is also an important aspect of the present invention to granu-late the slightly cross-linked theology modifying polymers or copolymers.
The same can be accomplished by processes known to the art and to the literature such as for example by roller compaction, by slugging, or utilizing wet methods such as a fluidized bed.
FIELD OF INVENTION
The present invention relates to slightly cross-linked polymers and copolymers generally derived from one or more unsaturated carboxylic acids, which are mixed with one or more active ingredients, and one or more excipients, wherein the mixture has desired properties such as good flow rates and appropriate compressibility so that without further processing it can flow through a die and be directly compressed into a tablet or other solid dosage article.
BACKGROUND OF THE INVENTION
1 ~ Heretofore, rheology agents were generally unsuitable for utiliza-tion in the formation of directly compressed tablets generally due to their fine particle size, static generating nature, and poor flow characteristics which they imparted to powder mixtures such as pharmaceutical mixtures.
In order to form such powder mixtures, a rheologic agent in the form of a ?0 non-granulated powder was mixed with an active ingredient and an excipi-ent and granulated. Subsequently, the granulated mixture was com-pressed into a tablet. The rheologic agents utilized included compounds such as Carbopol~ 934 PNF, 971 PNF, 974 PNF, 940, 941, and 934 made by B. F. Goodrich Company. Other similar rheologic agents include Syn-thalen K, L, and M made by 3V/Sigma, Hivis Wako made by Wako Pure Chemicals Co., and Aqupec made by Sumitomo Seika.
SUMMARY OF INVENTION
30 Solid dosage forms such as tablets for pharmaceutical uses are directly compressed from a mixture of granular rheology modifying poly-mers or copolymers, active ingredients, and excipients. The rheology modifier is a homopolymer or copolymer derived from one or more unsatu-rated carboxylic acids and is slightly cross-linked. The rheology modifying polymer or copolymer is processed into a desirable granular size as by be-ing compacted into large agglomerates or aggregates and subsequently fractured into smaller granules and generally screened to obtain suitable particle sizes which have low amounts of dust. The polymer or copolymer becomes highly swollen in an aqueous medium and is suitable for use in a human being or animal. The polymer or copolymer can be combined with numerous different types of active ingredients for one or more specific end uses. Moreover, numerous different types of excipients can be utilized.
The combination of the one or more excipients, active ingredients, and the theology modifying polymer or copolymer when mixed generally form suit-able mixtures for directly compressible tablets because of their good flow characteristics and compressibility.
DESCRIPTION OF THE DRAWINGS
1 ~ The figure is a schematic of a compaction/granulation appa-ratus.
DETAILED DESCRIPTION OF THE INVENTION
The polymeric theology modifier provides controlled release of ?0 biologically active compounds as contained in a tablet so that when placed in water, the modifier of the invention swells to form a viscous gel which retards diffusion of the active material. The theology modifying polymers or copolymers are derived from one or more unsaturated carboxylic acid monomers generally having one or two carboxylic acid groups, desirably having one carbon to carbon double bond and containing generally a total of from 3 to about 10 carbon atoms and preferably from 3 to about 5 car-bon atoms such as a-~3-unsaturated monocarboxylic acids, for example, acrylic acid, methacrylic acid, and crotonic acid, and the like, or dicarboxylic acids such as itaconic acid, fumaric acid, malefic acid, aconitic acid, and the 30 like. Moreover, half ester monomers of such diacids with alkanols contain-ing from 1 to about 4 carbon atoms can also be utilized. Preferred acids in-clude acrylic acid or malefic acid.
Optionally, one or more oxygen containing unsaturated co-monomers having a total of from 3 to about 40 carbon atoms, such as es-ters of the above unsaturated (di)carboxylic acids, that is mono or di, espe-cially alkyl esters containing a total of from 1 to about 30 carbon atoms in the alkyl group can also be utilized as comonomers to form the copolymer.
Examples of such esters include ethyl acrylate, butyl acrylate, 2-ethylhexyl acrylate, dodecyl acrylate, hexadecyl acrylate, and octadecyl acrylate, and the like, with the C,° to C3° acrylates being preferred.
Another optional class of comonomers are the various anhy-drides of the above noted carboxylic acids such as malefic anhydride, and the like. Moreover, another optional class of suitable comonomers are the various alkyl vinyl ethers wherein the alkyl group contains from 1 to about 1 > 20 carbon atoms with examples including ethyl vinyl ether, methyl vinyl ether, and the like.
The amount of the one or more oxygen containing acid co-monomers when utilized is generally a minor amount, such as from about 0.01 % to about 40% by weight, desirably from about 0.5% to about 35% by ?0 weight, and preferably from about 1 % to about 25% by weight based upon the total weight of all the Theology modifying polymer or copolymer forming monomers and comonomers. Thus, the amount of the one or more un-saturated carboxylic acid monomers, half esters thereof, or combinations thereof, is generally from about 60% to 99.99% by weight, desirably from about 65% to about 99.5% by weight, and preferably from about 75% to about 99% by weight based upon the total weight of all Theology modifying polymer or copolymer forming monomers or comonomers.
The various Theology modifying polymers or copolymers of the present invention are generally anhydrous. That is, they generally contain 30 5 parts by weight or less, desirably 3 parts or 2 parts by weight or less, and preferably 1 part or less by weight, and even nil, that is no parts by weight, of water per 100 parts by weight of the one or more rheology modifying polymers or copolymers.
The one or more rheology modifying polymers or copolymers also generally contain low amounts by weight of multivalent metal cations such as iron, for example 1 part by weight or less, desirably 0.1 part by weight or less, and preferably 0.01 part by weight or less per 100 parts by weight of all rheology modifying polymers or copolymers. The rheology modifying polymers or copolymers can contain up to five parts by weight of monovalent metal cations such as sodium, potassium, and the like.
It is an important aspect of the present invention that the rheol-ogy modifying polymer or copolymer be slightly cross-linked with one or more polyunsaturated monomers or comonomers. Suitable cross-linking agents generally include the various allyl ethers of sucrose or pentaerythri-tol, or derivatives thereof, or various polyalcohols. Specific examples in-I ~ clude; diallylphthalate, divinyl benzene, allyl (meth)acrylate, ethylene glycol di(meth)acrylate, divinylglycol methylene bisacrylamide, trimethylolpropane tri(meth)acrylate, diallyl itaconate, diallyl fumarate, or diallyl maleate. De-rivatives of castor oils or polyols such as esterfied with an ethylenically un-saturated carboxylic acid and the like can also be used. Preferred cross-~0 linking agents include allyl ether of sucrose, allyl ether of pentaerythritol, di-allylphthalate, and combinations thereof.
The amount of the cross-linking agent is from about 0.01 to about 2 parts by weight, desirably from about 0.02 to about 1.5 parts by weight, and preferably from about 0.03 to about 1 part by weight per 100 total parts by weight of the one or more monomers or comonomers.
Slightly cross-linked rheology modifying polymers or copolymers are util-ized inasmuch as they can conform under light pressure as in a compacting apparatus and in a mill to form granular mixtures which readily flow. Highly cross-linked rheology modifying polymers or copolymers tend to not con-30 form under light pressure and consequently fracture in a mill thus forming fine sized particles which do not readily flow and are therefore unsuitable for forming a directly compressed solid dosage form. Such moderate to highly cross-linked polymers or copolymers also tend to generate fisheyes therein. That is, when placed in water, they exhibit incompletely swollen particles easily visible in the transparent gel. , Examples of suitable slightly cross-linked commercially available theology modifying polymers or copolymers include Carbopol~, 941, 971 PNF and 981 manufactured by B. F.Goodrich, as well as Synthalen L made by 3V/Sigma, Aqupec HV-501 and HV 501 E made by Sumitomo Seika.
The polymers or copolymers of the present invention are pro-duced by conventional methods known to the art and to the literature such as by dispersion or precipitation polymerization utilizing suitable organic solvents such as various hydrocarbons, esters, halogenated hydrocarbon compounds and the like, with specific examples including aromatic solvents such as benzene, or toluene; various cycloaliphatic solvents such as cyclo-1 ~ hexane; various esters such as ethyl acetate and methyl formate, ethyl formate; various chlorinated hydrocarbons such as dichloromethane; and combinations thereof. Preferred solvents generally include benzene, meth-ylene chloride, blends of ethyl acetate and cyclohexane, or ethyl acetate, and the like.
'_'U The one or more monomers or comonomers are polymerized in a manner known to the art and to the literature such as described in U.S.
Patent Nos. 2,798,053; 3,915,921; 4,267,103; 5,288,814; and 5,349,030 which are hereby fully incorporated by reference. Desirably, the theology modifying polymers or copolymers have an acidic pH in water as from about 2.0 to about 4.0, desirably from about 2.5 to about 3.5.
It is also an important aspect of the present invention to granu-late the slightly cross-linked theology modifying polymers or copolymers.
The same can be accomplished by processes known to the art and to the literature such as for example by roller compaction, by slugging, or utilizing wet methods such as a fluidized bed.
A desired method for granulation is set forth in the drawing. A
granulator, generally indicated by the numeral 1, contains a feeder 10 which feeds the slightly cross-linked rheology modifying polymer, and co-polymer to the bottom of hopper 12. The polymer or copolymer is then fed through feed channel 14 to upper hopper 16. Hopper 16 additionally con-tains oversized and/or fine sized granulated polymers or copolymers which are not of a suitable size as set forth herein below. The slightly cross-linked polymer or copolymer in hopper 16, along with the oversized and/or fine sized granulated polymers or copolymers, is then fed via horizontal feed screw 18 to the granulator. The rate of rotation of horizontal feed screw 18 can be adjusted to permit continuous flow of the various sized polymers or copolymers into the granulator without clogging. Then, vertical screw 20 compresses and deaerates the various sized polymers or co-polymers fed thereto and feeds the same into compaction rollers 22. Hy-1 ~ draulic actuator 24 applies a suitable pressure to the compaction rollers.
Pressure is applied to the compaction rollers via the hydraulic actuator or other compaction device to produce a compacted material hav-ing a density of about 0.3 g/cc to about 1.5 g/cc. Preferably, the density of the compacted material is from about 0.38 g/cc to about 0.5 g/cc. These ?0 densities form strong enough aggregates and/or agglomerates such that the amount of undersized particles can be reduced without removing so much of the voids, cracks, and crevices (void volume) within the aggre-gates and agglomerates to prevent them from uniformly swelling in water or electrolyte solutions. The compaction rolls may have circumferential corru-gations, pocket indentations or corrugations in the axial direction across the width of the roll.
Desirably, the compaction rollers rotate in opposite directions so that the various sized rheology modifiers fed thereto are pulled between the rollers, compressed, and subsequently dropped downwardly into pre-break 30 mechanism 26. Pre-break mechanism 26 breaks the compressed various sized rheology modified chips into flakes which then fall into attritor 28.
The attritor subsequently further breaks up the chips into flakes which fall through screen 30. The granulated particles then fall into screening appa-ratus 32 which generally contains a plurality of screens which separate out oversized as well as undersized (i.e. fines) particles. The desired sized particles are fed to product bin 36. The over and undersized particles 38 are recycled through feed mechanism 40 which directs the same into feed channel 14 thereby recycling the oversized and undersized particles to up-per hopper 16. The above granulation procedure is set forth in U.S. Patent Application Serial No. 09/329,471, filed June 10, 1999 for 'Controlled Re-lease Polyacrylic Acid Granules and a Process for Preparing the Same' which is hereby fully incorporated by reference.
The granulated rheology modifying polymers and copolymers desirably have a specific particle size range so that when blended with the one or more active ingredients, and one or more excipients, a flowable 1 ~ mixture is produced. Desirably, the particle or granular size of the one or more polymers or copolymers can be classified as falling within size ranges as defined by U. S. Standard Mesh screens. For example, the particle size of the granulated rheology modifying polymers or copolymers is generally that which falls through 40 mesh but is retained on 200 mesh, desirably '_0 that which falls through 45 mesh but is retained on 150 mesh, and prefera-bly that which falls through 50 mesh but is retained upon a 100 mesh screen. The amount of oversized or undersized material which is con-tained within such ranges is also generally limited. For example, oversized material may be contained within a desired particle range as when the par-ticles are elongated. Undersized particles, or fines, can also be found within the desired particle size range as when the same stick to or are tied up between desired particle size products. The amount of the oversized material contained within the granular particles of the above desired ranges is generally about 5 percent or less, desirably about 3 percent or less, and 30 preferably about 1 percent or less by weight based upon the total weight of the particles falling through the larger sized mesh screen but retained on _g_ the smaller mesh screen. Similarly, the amount of fines contained within the granular particles of the above desired ranges is generally about 25 percent or less, desirably about 20 percent or less, and preferably ,about 15 percent by weight or less of the total particles which fall between the larger mesh screen but are retained by the smaller mesh screen. The net result is that suitable sized granules are utilized which flow freely through a die so that they can be directly compressed. As noted above, the same is not true of granular rheology modified particles made from moderate to highly cross-linked polymers or copolymers inasmuch as the same tend to frac-ture and form excessive amounts of fine sized particles which clog a de-sired diameter die, or other narrow constriction. If compressed to avoid the formation of excessive amounts of fine sized particles, the rheology modi-fied particles tend to form fisheyes as described above, and swelling is im-peded so that desirable control release properties are impaired.
I ~ The granulated slightly cross-linked rheology modifying polymers or copolymers of the present invention have several favorable properties such as thickening efficiency, bulk density, and tap density. When dis-persed in water at a concentration of 10 grams per liter and neutralized to a pH of 7, the granulated polymers or copolymers generally retain at least 70, 80, and even 90 percent of the thickening capacity of the original powder.
The viscosity of such a solution is desirably at least 350, 400, or 450, and preferably at least 1,400, 1,600, or 1,800 centipoise to about 16,000 centi-poise.
The bulk density of the granules is measured according to a typi-cal bulk density method for powders. A 30-100 mL cup is used which can be lightly tapped one time after filling. The powder is dropped from a pow-der funnel which discharges about 4 to 8 cm above the rim of the cup. The excess material which accumulates above the rim of the cup can be re-moved by scraping with a spatula and the weight of the contents deter-30 mined. The bulk density is the weight of the contents divided by their vol-ume. Suitable bulk densities generally range from about 0.35 to about 0.60 and desirably from about 0.38 to about 0.55 grams per cubic centimeter. A
tap density can also be determined using a 100 mL graduated cylinder in-stead of a cup. The powder is discharged from the bottom of a powder funnel as set forth above. A tap density apparatus such as a J. Engles-mann A-G Tap Density Apparatus is used to tap the cylinder and contents 1,000 times. The volume and weight of the powder after tapping is re-corded and the density is calculated as the weight divided by the volume.
Suitable tap densities range from about 0.40 to about 0.70, desirably from about 0.42 to about 0.60 and preferably from about 0.45 to about 0.58 grams per cubic centimeter.
An important component of the directly compressed solid dosage article such as a tablet is the utilization of an active ingredient. Such active ingredients) are generally classified as biological ingredients such as pharmaceutical, medicinal, nutritional, and the like.
I ~ Examples of biological ingredients include Tretinoin; Progester one; Methyl Salicylate; Capsaicin; Lidocaine; Prilocaine; Methyl Nicotin ate; Crotamiton; Avobenzone; Oxybenzone; Kaolin; Pectin; Sulfamethox azole; Fentoin; Albendazole; Pilocarpine HCI; Phenyipropanolamine HCI;
Fluocinonide; Formulated Actives in the 1998 Physicians Desk Refer ?0 ence~, and the like.
Various classes of medicinals which can be utilized include the following: androgenotherapy; anesthetic; anorectic; anti-allergy; anti-asthmatic; antibacterial; antibiotics; anti-depressants; antidermatosis;
anti-diarrhea; anti-emetics; antifungal; anti-inflammatory; anti-inflammatory analgesic; anti-inflammatory anti-pruritics; anti-inflammatory vasoconstrictive; anti-malaria; anti-parasitic; antiseptic; antiviral; anti-vomiting; bronchitis; burns; conjunctiva, cornea therapy; cough; estrogen;
gastro-intestinal treatment; glaucoma; hemorrhoid treatment; hair loss;
heart disease; heart-rhythm disorder; impotency; laxative; progestogen;
30 revulsive; slimming; spasmophilia; tooth health; urology; vein therapy;
wound treatment; and the like.
Various other active medicinal ingredients which can be utilized in-clude acetazolamide; aescin; aesculi hippocastan; allantoine; amfe-pramone; aminopropylon; amorolfine; androstanolone; arnica; bamethan sulfate; benproperinembonate; benzalkonium chloride; benzocaine; ben-zoyl peroxide; benzyl nicotinate; betamethasone; betaxolol chlohydrate;
buphenine hydrochloride; caffeine; calendula; campher; cetylpyridinium chloride; chloroquin phosphate; clarithromycin; clemastinhydrogene fuma-rate; clindamycin-2-dihydrogene phosphate; clobetasol-propionate; clo-trimazole; codeine phosphate; croconazole; crotamiton; dexamethasone acetate; dexpanthenol; diclofenac; diethylamine salicylate; diflucortolone;
diflucortolone valerate; diflucortolone, chlorquinaldol; difluoroprednate;
dimethyl sulfoxide; dimeticone 350-silicium dioxide; dimetinden; dimetin-denmaleat; disopyramide; domperidone; ergotoxine; estradiol; estriol;
etofenamate; felbinac; flubendazole; flufenamic acid; fluocinolone; fluo-1 ~ cinolone acetonide; fluocortolone; fusidic acid; gelacturoglycani;
heparine;
hydrocortisone; hydroxyethyl salicylate; ibuprofen; idoxuridine; imidazole salicylate; indomethacin; isoprenaline sulfate; ketoprofen; levomenthol;
lidocaine hydrochloride; lindane; menthol; mepyramine; mesalazine;
methyl nicotinate; methyl salicylate; metronidazole; miconazole; minoxidil;
''0 naftifin; nalixidic acid; naproxen; niflumic acid; nifuratel; nifuratel nystat-ine; nifuroxazide; nitroglycerin; nonivamid; nystatinnifuratel; omoconazole nitrate; o-rutoside; oxatomide; oxerutin; oxyphenbutazone; pancreatine;
pentosane polysulfate; phenolphthalein; phenylbutazone-piperazine;
phenylephrine; pilocarpine; piroxicam; plant extracts; polidocanol; poly-carbophil; polysaccharide; potassium phosphate; prednisolone; prilo-caine; primycin sulphate lidocaine; progesterone; proteins; ra-cem.campher; verapamil; viloxazine; vitamin B6; xylitol; xylometazoline;
zincum hyaluronicum, and the like.
Other active compounds include retacnyl tritinoine; retinol palmi 30 tate; salicylamide; salicylic acid; sobrerol; sodium alginate; sodium bicar bonate; sodium fluoride; sodium pentosan polysulfate; sodium phosphate;
terpine; theophylline; thromboplastin; thymol; tocopherol acetate; tolmetin;
tretinoin; troxerutine, and the like.
Various pharmaceutical ingredients which can be utilized include Ascorbic Acid; Guaifenesin; Quinidine Gluconate; Aspirin; Isosorbi,de Dinitrate; Quinidine Sulfatef; Atenolol; Isoniazid; Sodium Valproate; Car-amiphen HCI; Lithium Carbonate; Sulfamethizole; Chlorpheniramine Ma-leate; Mepyramine Maleate; Theophylline; Dexchlorpheniramine; Metha-done HCI; Thiamine; Diethyl Propion HCI; Metoclopramide;
Tridecamine; Diphenhydramine; Nitrofurantoin; Verapamil HCI;
Ephedrine HCI; Phenylpropanolamine HCI; Viloxazine; Furosemide;
Pseudoephedrine; 2-Ethylhexyl Salicylate; Clocortolone pivalate;
Kaolin; Permethrin; Adapalene; Crotamiton; Lidocaine; Phenylbenzimi dazole Sulfonic Acid; Albendazole; Desoximetasone; Menthol; Phenyl propanolamine; Avobenzone; Dimethicone; Mesalamine; Pilocarpine HCI;
1 s Benzalkonium Chloride; Methyl Nicotinate; Piperonyl Butoxide;
Benzocaine; Erythromycin; Methyl Salicylate; Prilocaine; Benzoyl Perox-ide; Ethylhexyl p-Methoxycinnamate; Metronidazole; Progesterone; Be-tamethasone dipropionate; Fenytoin; Naftifine HCI; Pyrethrum Extract;
Betaxolol HCI; Fluocinonide; Nalidixic acid; Rimexolone; Camphor; Guai-~0 fenesin; Nitrofurantoin; monohydrate; Simethicone; Capsaicins; Homo-salate; Octyl Methoxycinnamate; Sulfamethoxazole; Clarithromycin; Hy-drocortisone; Oxybenzone Tretinoin; Clindamycin phosphate; Hydrocorti-sone valerate; Padimate; Zinc Chloride; Clobetasol propionate; Hydroqui-none; Pectin; 2-Ethylhexyl Salicylate; Clocortolone pivalate; Kaolin; Per-methrin; Adapalene; Crotamiton; Lidocaine; Phenylbenzimidazole Sul-fonic Acid; Albendazole; Desoximetasone; Menthol; Phenylpropano-lamine; Avobenzone; Dimethicone; and Mesalamine.
As known to those skilled in the art and to the literature, the amount of the various active ingredients can vary widely, for example de-30 pending upon the type of end use, the biological or pharmaceutical activity of the ingredient, the desired biological pharmaceutical dose level, and the like. Thus, for example, the active ingredient can be used in an amount from a few parts per million up to approximately 80 percent by weight of the directly compressed tablet. , The excipients are generally utilized to give a desirable slow re-lease profile as well as other desirable attributes of a compressed tablet such as color, hardness, crushing strength, and low friability, etc. Accord-ingly, such excipients can be one or more fillers, binders, colorants, coating agents, slow release compounds, and the like.
In order to produce a flowable mixture which contains the slightly cross-linked rheology modified polymer or copolymers of the present inven-tion as well as the active ingredients, desirably only directly compressible excipients are utilized. Examples of some suitable excipients include mi-crocrystalline cellulose such as Avicel ~ PH101, Avicel ~ PH102, Avicel PH200, Avicel ~ PH301, and Avicel ~ PH302 available from FMC Corpo-1 ~ ration, Vivapur 101 and Virapur 102 available from Rettenmaier and Sohne GMBH , Emcocel 50 M and Emcocel 90 M available from Penwest Com-pany; dicalcium phosphate such as Elcema ~ available from Degussa; A-Tab~; DiTab ~ available from Rho-dia; lactose monohydrate such as Flow-Lac~ 100; Pharmatose~DCL11, Pharmatose~DCL15, Pharmatose~DCL21 available from DMV Interna-tional; Tablettose~ 80 available from Meggle; and tricalcium phosphate such as Tri-Tab ~; Fast Flo Lactose from Foremost: and Prosolve~ (Silici-fied MCC) from Penwest.
The amount of the one or more excipients utilized in the directly compressible solid dosage composition is simply the remainder of material required to make a suitable solid dosage form, for example a compressed tablet having a desired amount of active ingredient therein as well as a de-sirable amount of granulated slightly cross-linked rheology modifying poly-mer. Hence, the amounts of the excipient can vary widely.
The slightly cross-linked one or more rheology modifying poly-mers or copolymers, the one or more active ingredients, as well as the one or more excipients are mixed in any conventional manner to produce a blend. For example, it can be mixed in a shell blender, a Vee blender, a double-cone blender, a ribbon mixer, and the like. The mixture containing the granulated slightly cross-linked polymer or copolymer is then directly fed into generally any conventional tablet making machine wherein a de-sired amount of the mixture or blend is fed through an orifice or opening into a tablet die. The die is closed and compresses the mixture to produce a suitable sized and shaped solid dosage article such as a tablet. Unex-pectedly, use of the granulated slightly cross-linked rheology modifying polymer or copolymer in the mixture of the desirable directly compressible excipient and the active ingredient need not be granulated but, as stated herein above, directly fed into a directly compressing tablet forming ma-chine to form a solid dosage article and the like. That is, the present inven-tion is generally free of any other processing or compounding steps be-tween formation of the mixture or blend comprising the three above noted components and their formation of a solid dosage article.
An important aspect of the present invention is that the granular tableting mixtures have suitable flow properties or flow indices and the same can be readily determined in a manner known to the art and to the '?0 literature. For example, the flow index can be measured by FlodexTM
equipment, which comprises a 35-45 mm diameter tube approximately 8-10 cm long. Bottom caps with incrementally larger diameter apertures are used in the apparatus until the aperture is found of sufficient diameter that the contents of the tube are substantially emptied from the tube when the aperture is unblocked by the operator. A flow index value is assigned equal to the diameter of the aperture used in mm through which the mate-rial flows easily. If the aperture is too small, then bridging over occurs with a substantial amount of the tube contents being retained in the tube. The granular tableting mixtures of the present invention have FlodexT"" values 30 of generally 25 or 20 or less, desirably 15 or 10 or less, and preferably 8, 6, 5, or 4 or less, and even 3 or less.
Desirably, the flow characteristics of the compressible granular mixture of the present invention is such that it can flow through at least a hole of the same size or smaller than the die diameter in which the. tablet is to be made. In other words, if the tablet diameter is 16mm, the compressi-ble mixture should be able to flow through at least a 16mm hole, desirably at least a diameter of 1 mm smaller, i.e. 15mm, and preferably a diameter of at least 2mm less, i.e. 14mm or smaller.
The invention will be better understood by reference to the fol-lowing examples which serve to illustrate but not to limit the present inven-tion.
In the following examples, R is a rheology modifying polymer or copolymer, E is the excipient and AI is the active ingredient.
Exam~~le 1 i Ingredients Source % w/w Actual Weight(g) ' A,retaminnnhen /~,11 Cno~+mm2n r~ ~r~ n rWi ~.. ~~ ~.~ v. v .v Lactose Foremost 20.0 30.0 Monohydrate(E) I DiTab (E) Rhone- 20.0 30.0 I Poulenc I Emcompress (E) ~ Penwest 20.0 30.0 Granular Carbopol ~ BF Goodrich20.0 30.0 ~I
EX507* (R) l 1 ' Add tC V-Ble..de. Grams Acetaminophen 30.0 added to V-Blender Lactose Monohydrate 30.0 added to V-Blender Emcompress 30.0 added to V-Blender ~0 Carbopol EX507 30.0 added to V-Blender DiTab 30.0 added to V-Blender 2 ) The above formulation was blended for 15 minutes in a Patterson-Kelly Twin Shell Mixer (serial no. B10497).
3.) Placed in 8oz. jar and tested.
Ph~isical Properties of Formulation:
Flodex: 4 mm Flow Rate: 9.46 g/sec Bulk Density: 0.655 g/cc Tap Density: 0.790 g/cc Hausner Ratio 1.206 Compressibility: 17.09 Humidity: 14 * EX 507 is Carbopol~ 971 PNF which is manufactured and sold by B.F.Goodrich and is essentially a homopolymer of acrylic acid slightly cross-linked with allyl ether pentaerythritol, which has been granulated in a manner as set forth herein above.
Example 2 i -~..~...v..l: I of ~ w n 4 SOUii.e /o WIYv HCtUaI
my cmei mS ~
Weight(g) Acetaminophen Spectrum 20.0 30.0 (AI) ~ ~
Lactose Foremost 20.0 30.0 Monohydrate(E) DiTab (E) I Rhone- 20.0 30.0 ~ Poulenc i E o press (E) Penwest 20.0 30.0 i Granular Carbopol 20.0 30.0 BF Goodrich EX507 (R) ?0 1.) Add to V-Blender Grams Acetaminophen 30.0 added to V-Blender Lactose Monohydrate 30.0 added to V-Blender Emcompress 30.0 added to V-Blender Carbopol EX507 30.0 added to V-Blender 5 DiTab 30.0 added to V-Blender 2.) The above formulation was inutes in a Patterson-Kelly blended for 15 m Twin Shell Mixer (serial no. B10497).
3.) Placed in a 8oz. jar and tested.
Physical Properties of Formulation:
Flodex: 4 mm Flow Rate: 11.84 g/sec Bulk Density: 0.668 g/cc Tap Density: 0.821 g/cc Hausner Ratio: 1.229 Compressibility: 18.64 Humidity: 20 1~
'-0 Example 3 I I,n~rn~iienf~c,Cnyr~-n of ..~L..
v ~. i0 rri ~~.~ua~
rr Weight(g) Aces taminophen Spectrum 20.0 30.0 (AI) ' ~ Lactose Foremost 20.0 30.0 I Monohydrate (E) _ DiTab (E) ; Rhone- 20.0 30.0 ~
_ ' Poulenc ~
' 20.0 30.0 Emcompress (E) ~
' Penwest ~
' Granular Carbopol 20.0 30.0 BF Goodrich EX507(R) I
1.) Add to V-Blender Grams Acetaminophen 30.0 added to V-Blender Lactose Monohydrate 30.0 added to V-Blender Emcompress 30.0 added to V-Blender Carbopol EX507 30.0 added to V-Blender DiTab 30.0 added to V-Blender 2.) The above experimental formulation was blended for 25 minutes in a Patter-30 son-Kelly Twin Shell Mixer B10497).
(serial no.
3.) Placed in a 8oz. jar and tested.
Physical ProJ~erties of Formulation:
Flodex: 4 mm Flow Rate: 7.19 g/sec Bulk Density: 0.599 g/cc Tap Density: 0.731 g/cc Hausner Ratio: 1.220 Compressibility: 18.06 Humidity: 8 As apparent from above, the flow index of the compressible mixture of Examples 1, 2, and 3 which contained a granular theology modifying polymer was excellent,, i.e. readily being able to flow through a 4mm diameter orifice.
1 ~ In contrast, Examples 4 and 5 set forth below, which utilized the same granular theology modifying polymer, did not produce suitable low flow indexes for producing directly compressible mixtures because a di-rectly compressible excipient was not utilized.
Example 4 i Ingredients '~ Source % w/w Actual I ~ a n4vNn1 Nl,.i~...,m i Crystalline Acetamino- 20.0 30.0 Schweizerhall phen (AI) Crystalline Anhydrous ~ Sheffield60 g0 ~ Lactose(E) . .
Granular Carbopol ~ BF Goodrich20.0 30.0 i EX507(R) 1.) Add to V-Blender Grams Crystalline Acetaminophen 30.0 added to V-Blender Crystalline Anhydrous Lactose 90.0 added to V-Blender Granular Carbopol EX507 30.0 added to V-Blender 2.) The above formulation was blended for 15 minutes in a Patterson-Kelly Twin Shell Mixer (serial no. B10497).
3.) Placed in a 8oz. jar and tested.
Physical Properties of Formulatiow Flodex: 18 mm Flow Rate: 0 g/sec Bulk Density: 0.525 g/cc Tap Density: 0.708 g/cc Hausner Ratio: 1.349 Compressibility: 25.85 Humidity: 18 l~
Example 5 ;;.greuie~.ts ! Scarce i Actuai w/w Weight(g) ~ rystallme Theophyllme 32.9 98 Ruger 7 ! I .
Crystalline Anhydrous i Sheffield55.7 167.1 Lactose (E) i Granular Carbopol I BF Goodrich10.0 30.0 I
EX507(R) I Cab-O-Sil (E) Cabot ! 0.4 1.2 i Magnesium Stearate (E) . 3.0 Synpro I 1.0 1.) Mixed in a mortar & pestle Grams Cab-O-Sil 1.2 milled to a fine powder Theophylline 48.7 mixed in with the Cab-O-Sil transferred to V-Blender 2.) Add to V-Blender Grams Crystalline Theophylline 50.0 added to V-Blender Crystalline Anhydrous Lactose 67.1 added to V-Blender Crystalline Anhydrous Lactose 100.0 added to V-Blender Granular Carbopol EX507 30.0 added to V-Blender 3.) The above experimental formulation was blended for 25 minutes in a Patter-son-Kelly Twin Shell Mixer (serial no. 810497). , 4.) Mg. Stearate 3.0g was added to the formulation and blended for 2 minutes.
5) Divided into 100 gram samples and placed in three 8 oz. jars and tested.
Physical Properties of Formulation Flodex: 16 mm Flow Rate: 3.35 g/sec Bulk Density: 0.495 g/cc Tap Density: 0.634 g/cc Hausner Ratio: 1.281 Compressibility: 21.92 Humidity: g 1~
Example 6 Ingredients Source ~ % Actual w/w Weight(g) Crystalline TheophyllineRuger 32.g (AI) ~ Powder Carbopol BFGoodrich 10.0 971 PNF(R) Crystalline AnhydrousSheffield 55 Lactose (E) .
I Cab-O-Sil (E) Cabot 0.4 i __ I Synpro 1.0 Magnesium Stearate (E) I Total i 100 Example 6 was prepared in a manner similar to Example 5, that is, Cab-O-Sil and Theophylline were initially mixed in a mortar and pestle and then added to a Vee blender along with additional Crystalline Theo-phylline, the Crystalline Anhydrous Lactose and the Powder Carbopol and mixed for 25 minutes in a twin shell mixer, and the like. The following physical properties were obtained:
?5 Physical Properties of Formulation Flodex: 26 mm Flow Rate: no flow g/sec Bulk Density: 0.550 g/cc Tap Density: 0.753 g/cc Hausner Ratio: 1.369 Compressibility: 26.96 This Example shows that the use of a non-granulated rheology modifying polymer drastically reduced the flow rate rendering it totally un-acceptable for formation of a directly compressed solid article such as a tablet.
The granular mixtures of Examples 1 through 3 were tested in a tablet making machine and produced suitable direct compression tablets.
That is, the granular polymer containing mixture per se was compressed and formed in a tablet without any intervening, intermediate, or other steps.
Thus, the process for making the compressed tablets simply involves flowing the suitable amount of the granular rheology modifying polymer or copolymer, the active ingredient, and the excipient mixture into a die and compressing the same. The process is thus free of any other steps. The tablets produced by examples 1, 2 and 3 had good controlled released '?0 properties. That is the release time of the acetaminophen was 260 minutes when tested using synthetic intestinal fluid in a U. S. P. Type II paddle ap-paratus.
While in accordance with the Patent Statutes, the best mode and preferred embodiments have been set forth, the scope of the inven-tion is not limited thereto, but rather by the scope of the attached claims.
granulator, generally indicated by the numeral 1, contains a feeder 10 which feeds the slightly cross-linked rheology modifying polymer, and co-polymer to the bottom of hopper 12. The polymer or copolymer is then fed through feed channel 14 to upper hopper 16. Hopper 16 additionally con-tains oversized and/or fine sized granulated polymers or copolymers which are not of a suitable size as set forth herein below. The slightly cross-linked polymer or copolymer in hopper 16, along with the oversized and/or fine sized granulated polymers or copolymers, is then fed via horizontal feed screw 18 to the granulator. The rate of rotation of horizontal feed screw 18 can be adjusted to permit continuous flow of the various sized polymers or copolymers into the granulator without clogging. Then, vertical screw 20 compresses and deaerates the various sized polymers or co-polymers fed thereto and feeds the same into compaction rollers 22. Hy-1 ~ draulic actuator 24 applies a suitable pressure to the compaction rollers.
Pressure is applied to the compaction rollers via the hydraulic actuator or other compaction device to produce a compacted material hav-ing a density of about 0.3 g/cc to about 1.5 g/cc. Preferably, the density of the compacted material is from about 0.38 g/cc to about 0.5 g/cc. These ?0 densities form strong enough aggregates and/or agglomerates such that the amount of undersized particles can be reduced without removing so much of the voids, cracks, and crevices (void volume) within the aggre-gates and agglomerates to prevent them from uniformly swelling in water or electrolyte solutions. The compaction rolls may have circumferential corru-gations, pocket indentations or corrugations in the axial direction across the width of the roll.
Desirably, the compaction rollers rotate in opposite directions so that the various sized rheology modifiers fed thereto are pulled between the rollers, compressed, and subsequently dropped downwardly into pre-break 30 mechanism 26. Pre-break mechanism 26 breaks the compressed various sized rheology modified chips into flakes which then fall into attritor 28.
The attritor subsequently further breaks up the chips into flakes which fall through screen 30. The granulated particles then fall into screening appa-ratus 32 which generally contains a plurality of screens which separate out oversized as well as undersized (i.e. fines) particles. The desired sized particles are fed to product bin 36. The over and undersized particles 38 are recycled through feed mechanism 40 which directs the same into feed channel 14 thereby recycling the oversized and undersized particles to up-per hopper 16. The above granulation procedure is set forth in U.S. Patent Application Serial No. 09/329,471, filed June 10, 1999 for 'Controlled Re-lease Polyacrylic Acid Granules and a Process for Preparing the Same' which is hereby fully incorporated by reference.
The granulated rheology modifying polymers and copolymers desirably have a specific particle size range so that when blended with the one or more active ingredients, and one or more excipients, a flowable 1 ~ mixture is produced. Desirably, the particle or granular size of the one or more polymers or copolymers can be classified as falling within size ranges as defined by U. S. Standard Mesh screens. For example, the particle size of the granulated rheology modifying polymers or copolymers is generally that which falls through 40 mesh but is retained on 200 mesh, desirably '_0 that which falls through 45 mesh but is retained on 150 mesh, and prefera-bly that which falls through 50 mesh but is retained upon a 100 mesh screen. The amount of oversized or undersized material which is con-tained within such ranges is also generally limited. For example, oversized material may be contained within a desired particle range as when the par-ticles are elongated. Undersized particles, or fines, can also be found within the desired particle size range as when the same stick to or are tied up between desired particle size products. The amount of the oversized material contained within the granular particles of the above desired ranges is generally about 5 percent or less, desirably about 3 percent or less, and 30 preferably about 1 percent or less by weight based upon the total weight of the particles falling through the larger sized mesh screen but retained on _g_ the smaller mesh screen. Similarly, the amount of fines contained within the granular particles of the above desired ranges is generally about 25 percent or less, desirably about 20 percent or less, and preferably ,about 15 percent by weight or less of the total particles which fall between the larger mesh screen but are retained by the smaller mesh screen. The net result is that suitable sized granules are utilized which flow freely through a die so that they can be directly compressed. As noted above, the same is not true of granular rheology modified particles made from moderate to highly cross-linked polymers or copolymers inasmuch as the same tend to frac-ture and form excessive amounts of fine sized particles which clog a de-sired diameter die, or other narrow constriction. If compressed to avoid the formation of excessive amounts of fine sized particles, the rheology modi-fied particles tend to form fisheyes as described above, and swelling is im-peded so that desirable control release properties are impaired.
I ~ The granulated slightly cross-linked rheology modifying polymers or copolymers of the present invention have several favorable properties such as thickening efficiency, bulk density, and tap density. When dis-persed in water at a concentration of 10 grams per liter and neutralized to a pH of 7, the granulated polymers or copolymers generally retain at least 70, 80, and even 90 percent of the thickening capacity of the original powder.
The viscosity of such a solution is desirably at least 350, 400, or 450, and preferably at least 1,400, 1,600, or 1,800 centipoise to about 16,000 centi-poise.
The bulk density of the granules is measured according to a typi-cal bulk density method for powders. A 30-100 mL cup is used which can be lightly tapped one time after filling. The powder is dropped from a pow-der funnel which discharges about 4 to 8 cm above the rim of the cup. The excess material which accumulates above the rim of the cup can be re-moved by scraping with a spatula and the weight of the contents deter-30 mined. The bulk density is the weight of the contents divided by their vol-ume. Suitable bulk densities generally range from about 0.35 to about 0.60 and desirably from about 0.38 to about 0.55 grams per cubic centimeter. A
tap density can also be determined using a 100 mL graduated cylinder in-stead of a cup. The powder is discharged from the bottom of a powder funnel as set forth above. A tap density apparatus such as a J. Engles-mann A-G Tap Density Apparatus is used to tap the cylinder and contents 1,000 times. The volume and weight of the powder after tapping is re-corded and the density is calculated as the weight divided by the volume.
Suitable tap densities range from about 0.40 to about 0.70, desirably from about 0.42 to about 0.60 and preferably from about 0.45 to about 0.58 grams per cubic centimeter.
An important component of the directly compressed solid dosage article such as a tablet is the utilization of an active ingredient. Such active ingredients) are generally classified as biological ingredients such as pharmaceutical, medicinal, nutritional, and the like.
I ~ Examples of biological ingredients include Tretinoin; Progester one; Methyl Salicylate; Capsaicin; Lidocaine; Prilocaine; Methyl Nicotin ate; Crotamiton; Avobenzone; Oxybenzone; Kaolin; Pectin; Sulfamethox azole; Fentoin; Albendazole; Pilocarpine HCI; Phenyipropanolamine HCI;
Fluocinonide; Formulated Actives in the 1998 Physicians Desk Refer ?0 ence~, and the like.
Various classes of medicinals which can be utilized include the following: androgenotherapy; anesthetic; anorectic; anti-allergy; anti-asthmatic; antibacterial; antibiotics; anti-depressants; antidermatosis;
anti-diarrhea; anti-emetics; antifungal; anti-inflammatory; anti-inflammatory analgesic; anti-inflammatory anti-pruritics; anti-inflammatory vasoconstrictive; anti-malaria; anti-parasitic; antiseptic; antiviral; anti-vomiting; bronchitis; burns; conjunctiva, cornea therapy; cough; estrogen;
gastro-intestinal treatment; glaucoma; hemorrhoid treatment; hair loss;
heart disease; heart-rhythm disorder; impotency; laxative; progestogen;
30 revulsive; slimming; spasmophilia; tooth health; urology; vein therapy;
wound treatment; and the like.
Various other active medicinal ingredients which can be utilized in-clude acetazolamide; aescin; aesculi hippocastan; allantoine; amfe-pramone; aminopropylon; amorolfine; androstanolone; arnica; bamethan sulfate; benproperinembonate; benzalkonium chloride; benzocaine; ben-zoyl peroxide; benzyl nicotinate; betamethasone; betaxolol chlohydrate;
buphenine hydrochloride; caffeine; calendula; campher; cetylpyridinium chloride; chloroquin phosphate; clarithromycin; clemastinhydrogene fuma-rate; clindamycin-2-dihydrogene phosphate; clobetasol-propionate; clo-trimazole; codeine phosphate; croconazole; crotamiton; dexamethasone acetate; dexpanthenol; diclofenac; diethylamine salicylate; diflucortolone;
diflucortolone valerate; diflucortolone, chlorquinaldol; difluoroprednate;
dimethyl sulfoxide; dimeticone 350-silicium dioxide; dimetinden; dimetin-denmaleat; disopyramide; domperidone; ergotoxine; estradiol; estriol;
etofenamate; felbinac; flubendazole; flufenamic acid; fluocinolone; fluo-1 ~ cinolone acetonide; fluocortolone; fusidic acid; gelacturoglycani;
heparine;
hydrocortisone; hydroxyethyl salicylate; ibuprofen; idoxuridine; imidazole salicylate; indomethacin; isoprenaline sulfate; ketoprofen; levomenthol;
lidocaine hydrochloride; lindane; menthol; mepyramine; mesalazine;
methyl nicotinate; methyl salicylate; metronidazole; miconazole; minoxidil;
''0 naftifin; nalixidic acid; naproxen; niflumic acid; nifuratel; nifuratel nystat-ine; nifuroxazide; nitroglycerin; nonivamid; nystatinnifuratel; omoconazole nitrate; o-rutoside; oxatomide; oxerutin; oxyphenbutazone; pancreatine;
pentosane polysulfate; phenolphthalein; phenylbutazone-piperazine;
phenylephrine; pilocarpine; piroxicam; plant extracts; polidocanol; poly-carbophil; polysaccharide; potassium phosphate; prednisolone; prilo-caine; primycin sulphate lidocaine; progesterone; proteins; ra-cem.campher; verapamil; viloxazine; vitamin B6; xylitol; xylometazoline;
zincum hyaluronicum, and the like.
Other active compounds include retacnyl tritinoine; retinol palmi 30 tate; salicylamide; salicylic acid; sobrerol; sodium alginate; sodium bicar bonate; sodium fluoride; sodium pentosan polysulfate; sodium phosphate;
terpine; theophylline; thromboplastin; thymol; tocopherol acetate; tolmetin;
tretinoin; troxerutine, and the like.
Various pharmaceutical ingredients which can be utilized include Ascorbic Acid; Guaifenesin; Quinidine Gluconate; Aspirin; Isosorbi,de Dinitrate; Quinidine Sulfatef; Atenolol; Isoniazid; Sodium Valproate; Car-amiphen HCI; Lithium Carbonate; Sulfamethizole; Chlorpheniramine Ma-leate; Mepyramine Maleate; Theophylline; Dexchlorpheniramine; Metha-done HCI; Thiamine; Diethyl Propion HCI; Metoclopramide;
Tridecamine; Diphenhydramine; Nitrofurantoin; Verapamil HCI;
Ephedrine HCI; Phenylpropanolamine HCI; Viloxazine; Furosemide;
Pseudoephedrine; 2-Ethylhexyl Salicylate; Clocortolone pivalate;
Kaolin; Permethrin; Adapalene; Crotamiton; Lidocaine; Phenylbenzimi dazole Sulfonic Acid; Albendazole; Desoximetasone; Menthol; Phenyl propanolamine; Avobenzone; Dimethicone; Mesalamine; Pilocarpine HCI;
1 s Benzalkonium Chloride; Methyl Nicotinate; Piperonyl Butoxide;
Benzocaine; Erythromycin; Methyl Salicylate; Prilocaine; Benzoyl Perox-ide; Ethylhexyl p-Methoxycinnamate; Metronidazole; Progesterone; Be-tamethasone dipropionate; Fenytoin; Naftifine HCI; Pyrethrum Extract;
Betaxolol HCI; Fluocinonide; Nalidixic acid; Rimexolone; Camphor; Guai-~0 fenesin; Nitrofurantoin; monohydrate; Simethicone; Capsaicins; Homo-salate; Octyl Methoxycinnamate; Sulfamethoxazole; Clarithromycin; Hy-drocortisone; Oxybenzone Tretinoin; Clindamycin phosphate; Hydrocorti-sone valerate; Padimate; Zinc Chloride; Clobetasol propionate; Hydroqui-none; Pectin; 2-Ethylhexyl Salicylate; Clocortolone pivalate; Kaolin; Per-methrin; Adapalene; Crotamiton; Lidocaine; Phenylbenzimidazole Sul-fonic Acid; Albendazole; Desoximetasone; Menthol; Phenylpropano-lamine; Avobenzone; Dimethicone; and Mesalamine.
As known to those skilled in the art and to the literature, the amount of the various active ingredients can vary widely, for example de-30 pending upon the type of end use, the biological or pharmaceutical activity of the ingredient, the desired biological pharmaceutical dose level, and the like. Thus, for example, the active ingredient can be used in an amount from a few parts per million up to approximately 80 percent by weight of the directly compressed tablet. , The excipients are generally utilized to give a desirable slow re-lease profile as well as other desirable attributes of a compressed tablet such as color, hardness, crushing strength, and low friability, etc. Accord-ingly, such excipients can be one or more fillers, binders, colorants, coating agents, slow release compounds, and the like.
In order to produce a flowable mixture which contains the slightly cross-linked rheology modified polymer or copolymers of the present inven-tion as well as the active ingredients, desirably only directly compressible excipients are utilized. Examples of some suitable excipients include mi-crocrystalline cellulose such as Avicel ~ PH101, Avicel ~ PH102, Avicel PH200, Avicel ~ PH301, and Avicel ~ PH302 available from FMC Corpo-1 ~ ration, Vivapur 101 and Virapur 102 available from Rettenmaier and Sohne GMBH , Emcocel 50 M and Emcocel 90 M available from Penwest Com-pany; dicalcium phosphate such as Elcema ~ available from Degussa; A-Tab~; DiTab ~ available from Rho-dia; lactose monohydrate such as Flow-Lac~ 100; Pharmatose~DCL11, Pharmatose~DCL15, Pharmatose~DCL21 available from DMV Interna-tional; Tablettose~ 80 available from Meggle; and tricalcium phosphate such as Tri-Tab ~; Fast Flo Lactose from Foremost: and Prosolve~ (Silici-fied MCC) from Penwest.
The amount of the one or more excipients utilized in the directly compressible solid dosage composition is simply the remainder of material required to make a suitable solid dosage form, for example a compressed tablet having a desired amount of active ingredient therein as well as a de-sirable amount of granulated slightly cross-linked rheology modifying poly-mer. Hence, the amounts of the excipient can vary widely.
The slightly cross-linked one or more rheology modifying poly-mers or copolymers, the one or more active ingredients, as well as the one or more excipients are mixed in any conventional manner to produce a blend. For example, it can be mixed in a shell blender, a Vee blender, a double-cone blender, a ribbon mixer, and the like. The mixture containing the granulated slightly cross-linked polymer or copolymer is then directly fed into generally any conventional tablet making machine wherein a de-sired amount of the mixture or blend is fed through an orifice or opening into a tablet die. The die is closed and compresses the mixture to produce a suitable sized and shaped solid dosage article such as a tablet. Unex-pectedly, use of the granulated slightly cross-linked rheology modifying polymer or copolymer in the mixture of the desirable directly compressible excipient and the active ingredient need not be granulated but, as stated herein above, directly fed into a directly compressing tablet forming ma-chine to form a solid dosage article and the like. That is, the present inven-tion is generally free of any other processing or compounding steps be-tween formation of the mixture or blend comprising the three above noted components and their formation of a solid dosage article.
An important aspect of the present invention is that the granular tableting mixtures have suitable flow properties or flow indices and the same can be readily determined in a manner known to the art and to the '?0 literature. For example, the flow index can be measured by FlodexTM
equipment, which comprises a 35-45 mm diameter tube approximately 8-10 cm long. Bottom caps with incrementally larger diameter apertures are used in the apparatus until the aperture is found of sufficient diameter that the contents of the tube are substantially emptied from the tube when the aperture is unblocked by the operator. A flow index value is assigned equal to the diameter of the aperture used in mm through which the mate-rial flows easily. If the aperture is too small, then bridging over occurs with a substantial amount of the tube contents being retained in the tube. The granular tableting mixtures of the present invention have FlodexT"" values 30 of generally 25 or 20 or less, desirably 15 or 10 or less, and preferably 8, 6, 5, or 4 or less, and even 3 or less.
Desirably, the flow characteristics of the compressible granular mixture of the present invention is such that it can flow through at least a hole of the same size or smaller than the die diameter in which the. tablet is to be made. In other words, if the tablet diameter is 16mm, the compressi-ble mixture should be able to flow through at least a 16mm hole, desirably at least a diameter of 1 mm smaller, i.e. 15mm, and preferably a diameter of at least 2mm less, i.e. 14mm or smaller.
The invention will be better understood by reference to the fol-lowing examples which serve to illustrate but not to limit the present inven-tion.
In the following examples, R is a rheology modifying polymer or copolymer, E is the excipient and AI is the active ingredient.
Exam~~le 1 i Ingredients Source % w/w Actual Weight(g) ' A,retaminnnhen /~,11 Cno~+mm2n r~ ~r~ n rWi ~.. ~~ ~.~ v. v .v Lactose Foremost 20.0 30.0 Monohydrate(E) I DiTab (E) Rhone- 20.0 30.0 I Poulenc I Emcompress (E) ~ Penwest 20.0 30.0 Granular Carbopol ~ BF Goodrich20.0 30.0 ~I
EX507* (R) l 1 ' Add tC V-Ble..de. Grams Acetaminophen 30.0 added to V-Blender Lactose Monohydrate 30.0 added to V-Blender Emcompress 30.0 added to V-Blender ~0 Carbopol EX507 30.0 added to V-Blender DiTab 30.0 added to V-Blender 2 ) The above formulation was blended for 15 minutes in a Patterson-Kelly Twin Shell Mixer (serial no. B10497).
3.) Placed in 8oz. jar and tested.
Ph~isical Properties of Formulation:
Flodex: 4 mm Flow Rate: 9.46 g/sec Bulk Density: 0.655 g/cc Tap Density: 0.790 g/cc Hausner Ratio 1.206 Compressibility: 17.09 Humidity: 14 * EX 507 is Carbopol~ 971 PNF which is manufactured and sold by B.F.Goodrich and is essentially a homopolymer of acrylic acid slightly cross-linked with allyl ether pentaerythritol, which has been granulated in a manner as set forth herein above.
Example 2 i -~..~...v..l: I of ~ w n 4 SOUii.e /o WIYv HCtUaI
my cmei mS ~
Weight(g) Acetaminophen Spectrum 20.0 30.0 (AI) ~ ~
Lactose Foremost 20.0 30.0 Monohydrate(E) DiTab (E) I Rhone- 20.0 30.0 ~ Poulenc i E o press (E) Penwest 20.0 30.0 i Granular Carbopol 20.0 30.0 BF Goodrich EX507 (R) ?0 1.) Add to V-Blender Grams Acetaminophen 30.0 added to V-Blender Lactose Monohydrate 30.0 added to V-Blender Emcompress 30.0 added to V-Blender Carbopol EX507 30.0 added to V-Blender 5 DiTab 30.0 added to V-Blender 2.) The above formulation was inutes in a Patterson-Kelly blended for 15 m Twin Shell Mixer (serial no. B10497).
3.) Placed in a 8oz. jar and tested.
Physical Properties of Formulation:
Flodex: 4 mm Flow Rate: 11.84 g/sec Bulk Density: 0.668 g/cc Tap Density: 0.821 g/cc Hausner Ratio: 1.229 Compressibility: 18.64 Humidity: 20 1~
'-0 Example 3 I I,n~rn~iienf~c,Cnyr~-n of ..~L..
v ~. i0 rri ~~.~ua~
rr Weight(g) Aces taminophen Spectrum 20.0 30.0 (AI) ' ~ Lactose Foremost 20.0 30.0 I Monohydrate (E) _ DiTab (E) ; Rhone- 20.0 30.0 ~
_ ' Poulenc ~
' 20.0 30.0 Emcompress (E) ~
' Penwest ~
' Granular Carbopol 20.0 30.0 BF Goodrich EX507(R) I
1.) Add to V-Blender Grams Acetaminophen 30.0 added to V-Blender Lactose Monohydrate 30.0 added to V-Blender Emcompress 30.0 added to V-Blender Carbopol EX507 30.0 added to V-Blender DiTab 30.0 added to V-Blender 2.) The above experimental formulation was blended for 25 minutes in a Patter-30 son-Kelly Twin Shell Mixer B10497).
(serial no.
3.) Placed in a 8oz. jar and tested.
Physical ProJ~erties of Formulation:
Flodex: 4 mm Flow Rate: 7.19 g/sec Bulk Density: 0.599 g/cc Tap Density: 0.731 g/cc Hausner Ratio: 1.220 Compressibility: 18.06 Humidity: 8 As apparent from above, the flow index of the compressible mixture of Examples 1, 2, and 3 which contained a granular theology modifying polymer was excellent,, i.e. readily being able to flow through a 4mm diameter orifice.
1 ~ In contrast, Examples 4 and 5 set forth below, which utilized the same granular theology modifying polymer, did not produce suitable low flow indexes for producing directly compressible mixtures because a di-rectly compressible excipient was not utilized.
Example 4 i Ingredients '~ Source % w/w Actual I ~ a n4vNn1 Nl,.i~...,m i Crystalline Acetamino- 20.0 30.0 Schweizerhall phen (AI) Crystalline Anhydrous ~ Sheffield60 g0 ~ Lactose(E) . .
Granular Carbopol ~ BF Goodrich20.0 30.0 i EX507(R) 1.) Add to V-Blender Grams Crystalline Acetaminophen 30.0 added to V-Blender Crystalline Anhydrous Lactose 90.0 added to V-Blender Granular Carbopol EX507 30.0 added to V-Blender 2.) The above formulation was blended for 15 minutes in a Patterson-Kelly Twin Shell Mixer (serial no. B10497).
3.) Placed in a 8oz. jar and tested.
Physical Properties of Formulatiow Flodex: 18 mm Flow Rate: 0 g/sec Bulk Density: 0.525 g/cc Tap Density: 0.708 g/cc Hausner Ratio: 1.349 Compressibility: 25.85 Humidity: 18 l~
Example 5 ;;.greuie~.ts ! Scarce i Actuai w/w Weight(g) ~ rystallme Theophyllme 32.9 98 Ruger 7 ! I .
Crystalline Anhydrous i Sheffield55.7 167.1 Lactose (E) i Granular Carbopol I BF Goodrich10.0 30.0 I
EX507(R) I Cab-O-Sil (E) Cabot ! 0.4 1.2 i Magnesium Stearate (E) . 3.0 Synpro I 1.0 1.) Mixed in a mortar & pestle Grams Cab-O-Sil 1.2 milled to a fine powder Theophylline 48.7 mixed in with the Cab-O-Sil transferred to V-Blender 2.) Add to V-Blender Grams Crystalline Theophylline 50.0 added to V-Blender Crystalline Anhydrous Lactose 67.1 added to V-Blender Crystalline Anhydrous Lactose 100.0 added to V-Blender Granular Carbopol EX507 30.0 added to V-Blender 3.) The above experimental formulation was blended for 25 minutes in a Patter-son-Kelly Twin Shell Mixer (serial no. 810497). , 4.) Mg. Stearate 3.0g was added to the formulation and blended for 2 minutes.
5) Divided into 100 gram samples and placed in three 8 oz. jars and tested.
Physical Properties of Formulation Flodex: 16 mm Flow Rate: 3.35 g/sec Bulk Density: 0.495 g/cc Tap Density: 0.634 g/cc Hausner Ratio: 1.281 Compressibility: 21.92 Humidity: g 1~
Example 6 Ingredients Source ~ % Actual w/w Weight(g) Crystalline TheophyllineRuger 32.g (AI) ~ Powder Carbopol BFGoodrich 10.0 971 PNF(R) Crystalline AnhydrousSheffield 55 Lactose (E) .
I Cab-O-Sil (E) Cabot 0.4 i __ I Synpro 1.0 Magnesium Stearate (E) I Total i 100 Example 6 was prepared in a manner similar to Example 5, that is, Cab-O-Sil and Theophylline were initially mixed in a mortar and pestle and then added to a Vee blender along with additional Crystalline Theo-phylline, the Crystalline Anhydrous Lactose and the Powder Carbopol and mixed for 25 minutes in a twin shell mixer, and the like. The following physical properties were obtained:
?5 Physical Properties of Formulation Flodex: 26 mm Flow Rate: no flow g/sec Bulk Density: 0.550 g/cc Tap Density: 0.753 g/cc Hausner Ratio: 1.369 Compressibility: 26.96 This Example shows that the use of a non-granulated rheology modifying polymer drastically reduced the flow rate rendering it totally un-acceptable for formation of a directly compressed solid article such as a tablet.
The granular mixtures of Examples 1 through 3 were tested in a tablet making machine and produced suitable direct compression tablets.
That is, the granular polymer containing mixture per se was compressed and formed in a tablet without any intervening, intermediate, or other steps.
Thus, the process for making the compressed tablets simply involves flowing the suitable amount of the granular rheology modifying polymer or copolymer, the active ingredient, and the excipient mixture into a die and compressing the same. The process is thus free of any other steps. The tablets produced by examples 1, 2 and 3 had good controlled released '?0 properties. That is the release time of the acetaminophen was 260 minutes when tested using synthetic intestinal fluid in a U. S. P. Type II paddle ap-paratus.
While in accordance with the Patent Statutes, the best mode and preferred embodiments have been set forth, the scope of the inven-tion is not limited thereto, but rather by the scope of the attached claims.
Claims (29)
1. A solid dosage article, comprising:
a directly compressed blend of , a) a granulated slightly cross-linked rheology modifying polymer or copolymer derived from at least one unsaturated (di)carboxylic acid monomer having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, and op-tionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon atoms, and a cross-linking agent;
b) one or more active ingredients; and c) one or more excipients.
a directly compressed blend of , a) a granulated slightly cross-linked rheology modifying polymer or copolymer derived from at least one unsaturated (di)carboxylic acid monomer having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, and op-tionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon atoms, and a cross-linking agent;
b) one or more active ingredients; and c) one or more excipients.
2. A solid dosage article according to claim 1, wherein said one or more oxygen containing unsaturated comonomers comprises an anhy-dride of said unsaturated carboxylic acid, or an alkyl ester of said unsatu-rated carboxylic acid wherein said alkyl group has from 1 to about 30 car-bon atoms, or an alkyl vinyl ether wherein said alkyl group has from 1 to about 20 carbon atoms, or combinations thereof, wherein said slightly cross-linked granulated rheology modifying polymer or copolymer has a particle size of from about 40 mesh to about 200 U.S. Standard Mesh, and wherein said excipient is a directly compressible excipient.
3. A solid dosage article according to claim 2, wherein said un-saturated carboxylic acid has from 3 to about 5 carbon atoms, wherein the amount of said one or more oxygen containing comonomers when utilized is from about 0.01 to about 40 percent by weight, wherein the amount of said unsaturated carboxylic acid monomer or said half ester monomer or combination thereof is from about 60 to about 99.99 percent by weight based upon the total weight of said monomers and comonomers, and wherein the amount of said cross-linking agent is from about 0.01 to about 2.0 parts by weight per 100 parts by weight of said monomers and co-monomers.
4. A solid dosage article according to claim 3, wherein said slightly cross-linked granulated rheology modifying polymer or copolymer has a particle size of from about 45 to about 150 U.S. Standard Mesh, and wherein said cross-linking agent is an allyl ether of sucrose or pentaeryth-ritol, or a derivative thereof, a polyalcohol, diallylphthalate, divinyl benzene, allyl (meth)acrylate, ethylene glycol di(meth)acrylate, methylene bisac-rylamide, trimethylolpropane tri(meth)acrylate, diallyl itaconate, diallyl fuma-rate, diallyl maleate, castor oil or a polyol esterfied with an ethylenically un-saturated carboxylic acid, or combinations thereof.
5. A solid dosage article according to claim 4, wherein said rhe-ology modifying polymer or copolymer is derived from acrylic acid or maleic acid, or combinations thereof, wherein said cross-linking agent is an allyl ether of sucrose, an allyl ether of pentaerythritol, or diallylphthalate, or combinations thereof, and wherein the amount of said cross-linking agent is from about 0.03 to about 1.0 part by weight per 100 parts by weight of said monomers and comonomers.
6. A solid dosage article according to claim 1, wherein said granulated rheology modifying polymer or copolymer contains less than about 5 parts by weight of water per 100 parts by weight of said granulated rheology modifying polymer or copolymer, and wherein said granulated rheology modifying polymer or copolymer contains less than about 1 part by weight of a multivalent metal cation per 100 parts by weight of said granulated rheology modifying polymer and copolymer.
7. A solid dosage article according to claim 3, wherein said granulated rheology modifying polymer or copolymer contains less than about 5 parts by weight of water per 100 parts by weight of said granulated rheology modifying polymer or copolymer, and wherein said granulated rheology modifying polymer or copolymer contains less than about 1 part by weight of a multivalent metal cation per 100 parts by weight of said granulated rheology modifying polymer and copolymer.
8. A solid dosage article according to claim 5, wherein said granulated rheology modifying polymer or copolymer contains less than about 2 parts by weight of water per 100 parts by weight of said granulated rheology modifying polymer or copolymer, and wherein said granulated rheology modifying polymer or copolymer contains less than about 0.1 part by weight of a multivalent metal cation per 100 parts by weight of said granulated rheology modifying polymer or copolymer.
9. A control release article comprising the directly compressed solid dosage article of claim 1.
10. A control release article comprising the directly compressed solid dosage article of claim 3.
11. A control release article comprising the directly compressed solid dosage article of claim 5.
12. A directly compressed solid dosage article according to claim 1, wherein said article is a tablet.
13. A directly compressed solid dosage article according to claim 3, wherein said article is a tablet.
14. A directly compressed solid dosage article according to claim 5, wherein said article is a tablet.
15. A process for the direct compression of solid dosage arti-cles, comprising the steps of:
mixing a granulated slightly cross-linked rheology modifying polymer or copolymer with one or more active ingredients and one or more excipients, said slightly cross-linked rheology modifying polymer or copoly-mer derived from at least one unsaturated (di)carboxylic acid monomer having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, and optionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon atoms, and a cross-linking agent, said slightly granulated cross-linked polymer or copolymer having a particle size of from about 40 to about 200 U.S. Standard Mesh;
forming a flowable mixture, and directly compressing said mixture to produce a solid article.
mixing a granulated slightly cross-linked rheology modifying polymer or copolymer with one or more active ingredients and one or more excipients, said slightly cross-linked rheology modifying polymer or copoly-mer derived from at least one unsaturated (di)carboxylic acid monomer having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, and optionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon atoms, and a cross-linking agent, said slightly granulated cross-linked polymer or copolymer having a particle size of from about 40 to about 200 U.S. Standard Mesh;
forming a flowable mixture, and directly compressing said mixture to produce a solid article.
16. A process according to claim 15, wherein said one or more oxygen containing unsaturated comonomers comprises an anhydride of said unsaturated carboxylic acid, or an alkyl ester of said unsaturated car-boxylic acid wherein said alkyl group has from 1 to about 30 carbon atoms, or an alkyl vinyl ether wherein said alkyl group has from 1 to about 20 car-bon atoms, or combinations thereof, and wherein said excipient is a directly compressible excipient.
17. A process according to claim 16, wherein said unsaturated carboxylic acid has from 3 to about 5 carbon atoms, wherein the amount of said one or more oxygen containing comonomers when utilized is from about 0.01 to about 40 percent by weight, wherein the amount of said un-saturated carboxylic acid monomer or said half ester monomer or combina-tion thereof is from about 60 to about 99.99 percent by weight based upon the total weight of said monomers and comonomers, wherein the amount of said cross-linking agent is from about 0.01 to about 2.0 parts by weight per 100 parts by weight of said monomers and comonomers, wherein said slightly cross-linked granulated rheologic modifying polymer or copolymer has a particle size of from about 45 to about 150 U.S. Standard Mesh, and wherein said cross-linking agent is an allyl ether of sucrose or pentaeryth-ritol, or a derivative thereof, a polyalcohol, diallylphthalate, divinyl benzene, allyl (meth)acrylate, ethylene glycol di(meth)acrylate, methylene bisac-rylamide, trimethylolpropane tri(meth)acrylate, diallyl itaconate, diallyl fuma-rate, diallyl maleate, castor oil or a polyol esterfied with an ethylenically un-saturated carboxylic acid, or combinations thereof.
18. A process according to claim 17, wherein the amount of said cross-linking agent is from about 0.02 to about 1.5 parts by weight per 100 parts by weight of said monomers and comonomers, and wherein said par-ticle size is from about 50 to about 100 U.S. Standard Mesh.
19. A process according to claim 18, wherein said polymer or copolymer is derived from acrylic acid, maleic acid, or combinations thereof, and wherein said cross-linking agent is an allyl ether of sucrose, an allyl ether of pentaerythritol, or diallylphthalate, or combinations thereof.
20. A directly compressible mixture, comprising:
a granulated slightly cross-linked rheology modifying polymer or copolymer derived from at least one unsaturated (di)carboxylic acid mono-mer having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, optionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon atoms, and a cross-linking agent;
one or more excipients; and one or more active ingredients.
a granulated slightly cross-linked rheology modifying polymer or copolymer derived from at least one unsaturated (di)carboxylic acid mono-mer having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, optionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon atoms, and a cross-linking agent;
one or more excipients; and one or more active ingredients.
21. A directly compressible mixture according to claim 20, wherein said one or more oxygen containing unsaturated comonomers comprises an anhydride of said unsaturated carboxylic acid, or an alkyl ester of said unsaturated carboxylic acid wherein said alkyl group has from 1 to about 30 carbon atoms, or an alkyl vinyl ether wherein said alkyl group has from 1 to about 20 carbon atoms, or combinations thereof, wherein the amount of said one or more oxygen containing comonomers when utilized is from about 0.01 to about 40 percent by weight, wherein the amount of said unsaturated carboxylic acid monomer or said half ester monomer or combination thereof is from about 60 to about 99.99 percent by weight based upon the total weight of said monomers and comonomers, wherein said granulated rheologic modifying polymer or copolymer has a particle size of from about 40 Mesh to about 200 U.S. Standard Mesh, and wherein said excipient is a directly compressible excipient.
22. A directly compressible mixture according to claim 21, wherein said unsaturated carboxylic acid has from 3 to about 5 carbon at-oms, and wherein the amount of said cross-linking agent is from about 0.01 to about 2.0 part by weight per 100 parts by weight of said rheology modi-fying monomers and comonomers.
23. A directly compressible mixture according to claim 22, wherein said granulated rheology modifying polymer or copolymer is a polymer derived from a monomer comprising acrylic acid, wherein said cross-linking agent is an allyl ether of sucrose, an allyl ether of pentaeryth-ritol, or diallylphthalate, or combinations thereof, wherein the amount of said cross-linking agent is from about 0.03 to about 1.0 part by weight per 100 parts by weight of said rheology modifying monomers or comonomers, and wherein said rheology modifying polymer or copolymer has a particle size of from about 45 U.S. Mesh to 150 U.S. Mesh.
24. A directly compressible mixture according to claim 20, hav-ing a Flodex of about 25 or less.
25. A directly compressible mixture according to claim 23, hav-ing a Flodex of about 5 or less.
26. A process for forming a directly compressible mixture, com-prising the steps:
mixing a granulated slightly cross-linked rheology modifying polymer or copolymer with one or more active ingredients and one or more excipients, said slightly cross-linked rheology modifying polymer or copoly-mer derived from at least one unsaturated (di)carboxylic acid having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, optionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon at-oms. and a cross-linking agent; said granulated slightly cross-linked poly-mer or copolymer having a particle size of from about 40 to about 200 U.S.
Standard Mesh; and forming a flowable mixture.
mixing a granulated slightly cross-linked rheology modifying polymer or copolymer with one or more active ingredients and one or more excipients, said slightly cross-linked rheology modifying polymer or copoly-mer derived from at least one unsaturated (di)carboxylic acid having a total of from 3 to about 10 carbon atoms, or at least one half ester monomer of said unsaturated dicarboxylic acid with an alkanol having from 1 to about 4 carbon atoms, or combinations thereof, optionally one or more oxygen containing unsaturated comonomers having from 3 to about 40 carbon at-oms. and a cross-linking agent; said granulated slightly cross-linked poly-mer or copolymer having a particle size of from about 40 to about 200 U.S.
Standard Mesh; and forming a flowable mixture.
27. A process according to claim 26, wherein said unsaturated carboxylic acid has from 3 to about 5 carbon atoms, wherein said one or more oxygen containing unsaturated comonomers comprises an anhydride of said unsaturated carboxylic acid, or an alkyl ester of said unsaturated carboxylic acid wherein said alkyl group has from 1 to about 30 carbon at-oms, or an alkyl vinyl ether wherein said alkyl group has from 1 to about 20 carbon atoms, or combinations thereof, wherein the amount of said one or more oxygen containing comonomers when utilized is from about 0.01 to about 40 percent by weight, wherein the amount of said unsaturated car-boxylic acid monomer or said half ester monomer or combination thereof is from about 60 to about 99.99 percent by weight based upon the total weight of said monomers and comonomers, wherein the particle size of said granulated slightly cross-linked rheology modifying polymer or copoly-mer is from about 45 to about 150 U.S. Standard Mesh, and wherein said directly compressible mixture has a Flodex of about 25 or less.
28. A process according to claim 27, wherein said slightly cross-linked granulated rheologic modifying polymer or copolymer has a particle size of from about 45 to about 150 U.S. Standard Mesh, wherein said cross-linking agent is an allyl ether of sucrose or penta-erythritol, or a de-rivative thereof, a polyalcohol, diallylphthalate, divinyl benzene, allyl (meth)acrylate, ethylene glycol di(meth)acrylate, methy-lene bisacrylamide, trimethylolpropane tri(meth)acrylate, diallyl itaconate, diallyl fumarate, diallyl maleate, castor oil or a polyol esterfied with an ethylenically unsaturated carboxylic acid, or combinations thereof, and wherein said compressible mixture has a Flodex of about 20 or less.
29. A process according to claim 28, wherein said rheology modifying polymer or copolymer is derived from acrylic acid, or malefic acid, or combinations thereof, wherein said cross-linking agent is an allyl ether of sucrose, an allyl ether of pentaerythritol, or diallylphthalate, or combinations thereof, wherein the amount of said cross-linking agent is from about 0.03 to about 1.0 part by weight per 100 parts by weight of said monomers and comonomers, and wherein said directly compressible mixture has a Flodex of about 6 or less.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/559,687 | 2000-04-27 | ||
| US09/559,687 US6623756B1 (en) | 2000-04-27 | 2000-04-27 | Directly compressed solid dosage articles |
| PCT/US2001/012400 WO2001082894A2 (en) | 2000-04-27 | 2001-04-17 | Directly compressed solid dosage particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2407140A1 true CA2407140A1 (en) | 2001-11-08 |
Family
ID=24234605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002407140A Abandoned CA2407140A1 (en) | 2000-04-27 | 2001-04-17 | Directly compressed solid dosage particles |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6623756B1 (en) |
| EP (1) | EP1276466B1 (en) |
| JP (1) | JP2003531848A (en) |
| CN (1) | CN1195498C (en) |
| AT (1) | ATE255886T1 (en) |
| BR (1) | BR0110287A (en) |
| CA (1) | CA2407140A1 (en) |
| DE (1) | DE60101468T2 (en) |
| ES (1) | ES2211796T3 (en) |
| IL (2) | IL152461A0 (en) |
| MX (1) | MXPA02010437A (en) |
| WO (1) | WO2001082894A2 (en) |
| ZA (1) | ZA200208571B (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
| US6623754B2 (en) * | 2001-05-21 | 2003-09-23 | Noveon Ip Holdings Corp. | Dosage form of N-acetyl cysteine |
| US20030012820A1 (en) * | 2001-06-12 | 2003-01-16 | Upadhyay Ajay Hasmukhlal | Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom |
| US6705028B2 (en) * | 2001-09-12 | 2004-03-16 | Honda Giken Kogyo Kabushiki Kaisha | Self-propelled snowplow vehicle |
| US20040185016A1 (en) * | 2002-07-30 | 2004-09-23 | Popp Karl F | Compositions for treatment of hyperpigmentation and methods for making and using such compositions |
| US20040219210A1 (en) * | 2003-05-01 | 2004-11-04 | Jian-Hwa Guo | Controlled release solid dosage nifedipine formulations |
| US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
| US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
| US20070077297A1 (en) * | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| FI20080353A0 (en) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Process for preparing a tablet with extra high drug content |
| FI20080346A0 (en) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Process for making a tablet containing additives |
| FI20080355A0 (en) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Process for making tablets containing metformin |
| US7749537B2 (en) * | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
| CN101467988B (en) * | 2007-12-27 | 2014-07-09 | 北京德众万全医药科技有限公司 | Medicament composition containing paracetamol and pseudoephedrine hydrochloride and preparation method thereof |
| US20110284573A1 (en) * | 2008-12-17 | 2011-11-24 | Allan Dagsland | Method of providing a target dose, powder provider device and its use |
| AR077712A1 (en) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | SERINA PROTEASA MACROCICLICA INHIBITORS |
| WO2011056764A1 (en) | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
| CN102822175A (en) | 2009-12-18 | 2012-12-12 | 埃迪尼克斯医药公司 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2011112689A2 (en) | 2010-03-11 | 2011-09-15 | Ambit Biosciences Corp. | Saltz of an indazolylpyrrolotriazine |
| EP2611795B1 (en) | 2010-09-01 | 2016-05-04 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
| CA2809983A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Hydrobromide salts of a pyrazolylaminoquinazoline |
| US20140079686A1 (en) | 2010-12-06 | 2014-03-20 | Shikha P. Barman | Methods For Treating Baldness And Promoting Hair Growth |
| WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
| CA2825152A1 (en) | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| TW201309690A (en) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| WO2013138617A1 (en) | 2012-03-16 | 2013-09-19 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| EP3114122A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| CA2943231C (en) | 2014-03-20 | 2023-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| ES2891734T3 (en) | 2014-03-20 | 2022-01-31 | Capella Therapeutics Inc | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for cancer treatment |
| WO2016106309A1 (en) | 2014-12-23 | 2016-06-30 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| CA3001337C (en) | 2015-10-09 | 2023-12-12 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| US20220072493A1 (en) | 2019-01-24 | 2022-03-10 | Novo Nordisk A/S | Roller compactor and method of dry granulation using a roller compactor |
| US20220323360A1 (en) | 2019-09-06 | 2022-10-13 | Novo Nordisk A/S | Method and equipment for fractionation of granules for use in pharmaceutical compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) * | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US3915921A (en) * | 1974-07-02 | 1975-10-28 | Goodrich Co B F | Unsaturated carboxylic acid-long chain alkyl ester copolymers and tri-polymers water thickening agents and emulsifiers |
| US4267103A (en) * | 1978-12-07 | 1981-05-12 | The B. F. Goodrich Company | Solvent polymerization of carboxyl containing monomers |
| US4952651A (en) * | 1988-03-30 | 1990-08-28 | Japan Synthetic Rubber Co., Ltd. | Highly crosslinked polymer particles and process for producing the same |
| ATE209228T1 (en) * | 1992-05-09 | 2001-12-15 | Surfachem Group Ltd | CONVERSION OF POWDERED POLYMERS |
| US5288814A (en) * | 1992-08-26 | 1994-02-22 | The B. F. Goodrich Company | Easy to disperse polycarboxylic acid thickeners |
| US5780055A (en) * | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
-
2000
- 2000-04-27 US US09/559,687 patent/US6623756B1/en not_active Expired - Fee Related
-
2001
- 2001-04-17 BR BR0110287-7A patent/BR0110287A/en not_active Application Discontinuation
- 2001-04-17 AT AT01925043T patent/ATE255886T1/en not_active IP Right Cessation
- 2001-04-17 DE DE60101468T patent/DE60101468T2/en not_active Expired - Lifetime
- 2001-04-17 JP JP2001579769A patent/JP2003531848A/en not_active Withdrawn
- 2001-04-17 MX MXPA02010437A patent/MXPA02010437A/en active IP Right Grant
- 2001-04-17 CN CNB018086330A patent/CN1195498C/en not_active Expired - Fee Related
- 2001-04-17 EP EP01925043A patent/EP1276466B1/en not_active Expired - Lifetime
- 2001-04-17 CA CA002407140A patent/CA2407140A1/en not_active Abandoned
- 2001-04-17 IL IL15246101A patent/IL152461A0/en active IP Right Grant
- 2001-04-17 WO PCT/US2001/012400 patent/WO2001082894A2/en active IP Right Grant
- 2001-04-17 ES ES01925043T patent/ES2211796T3/en not_active Expired - Lifetime
-
2002
- 2002-10-23 ZA ZA200208571A patent/ZA200208571B/en unknown
- 2002-10-24 IL IL152461A patent/IL152461A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60101468T2 (en) | 2004-10-28 |
| IL152461A (en) | 2007-08-19 |
| WO2001082894A2 (en) | 2001-11-08 |
| JP2003531848A (en) | 2003-10-28 |
| US6623756B1 (en) | 2003-09-23 |
| MXPA02010437A (en) | 2003-04-25 |
| BR0110287A (en) | 2003-02-18 |
| IL152461A0 (en) | 2003-05-29 |
| CN1426297A (en) | 2003-06-25 |
| EP1276466B1 (en) | 2003-12-10 |
| DE60101468D1 (en) | 2004-01-22 |
| WO2001082894A3 (en) | 2002-02-21 |
| EP1276466A2 (en) | 2003-01-22 |
| ATE255886T1 (en) | 2003-12-15 |
| ZA200208571B (en) | 2003-08-19 |
| CN1195498C (en) | 2005-04-06 |
| ES2211796T3 (en) | 2004-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6623756B1 (en) | Directly compressed solid dosage articles | |
| US6623754B2 (en) | Dosage form of N-acetyl cysteine | |
| CA1287582C (en) | Sustained release compositions comprising hydroxypropyl cellulose ethers | |
| EP1138321B1 (en) | Solid oral dosage forms with sustained drug release and high mechanical stability | |
| DE69929439T2 (en) | POLYACRYLIC ACID GRANULES WITH A TAX RELEASE AND METHOD FOR THE PRODUCTION THEREOF | |
| JP5612462B2 (en) | Particulate material for dosage forms | |
| US7179486B1 (en) | Process for preparing sustained release tablets | |
| EP3174530B1 (en) | Directly compressible polyvinyl alcohols | |
| DE19709663A1 (en) | Use of redispersible polymer powders or polymer granules as binders for the production of solid pharmaceutical dosage forms | |
| DE1279896B (en) | The use of an acidic copolymer for the production of tablets with prolonged drug release | |
| EP3174531A1 (en) | Directly compressible composition containing micro-crystalline cellulose | |
| EP0950404B1 (en) | Process for the preparation of solid dosage forms | |
| US8114905B2 (en) | Compacted 2,2-dibromo-3-nitrilopropionamide | |
| DE4414544C2 (en) | Deposit tablet | |
| DE60218744T2 (en) | PARTICULAR COMPOSITION CONTAINING A LIPOPHILIC LIQUID | |
| EP0537139B1 (en) | Process for producing pressed, moulded, delayed release dose units and dose units thus produced | |
| EP0873114B1 (en) | Granulates for cosmetic and pharmaceutical preparations | |
| Jagtap et al. | Development of directly compressible ascorbic acid tablet using novel excipients | |
| JP6506752B2 (en) | Super fast disintegrating tablet formulation for API miglitol | |
| DE60223695T2 (en) | AMINO ACID-MODULATED DOSAGE FORM WITH EXTENDED RELEASE | |
| DD238528A1 (en) | METHOD FOR PRODUCING PEROAL MEDICAMENTS WITH DELAYED ACTIVE INGREDIENT TRANSFER | |
| JP2004123731A (en) | Tablet formulated with dioctyl sodium sulfosuccinate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |